An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study

JAMA Dermatol. 2014 Sep;150(9):1013-4. doi: 10.1001/jamadermatol.2013.10526.

Authors

Bobbye J Thompson¹, Megan Furniss¹, Wenjing Zhao², Bibhas Chakraborty², Julian Mackay-Wiggan¹

Affiliations

¹ Department of Dermatology, Columbia University, New York, New York.
² Department of Biostatistics, Columbia University, New York, New York.

PMID: 25054629
DOI: 10.1001/jamadermatol.2013.10526

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Adult
Aged
Female
Humans
Male
Middle Aged
Phosphodiesterase Inhibitors / administration & dosage*
Pilot Projects
Rosacea / drug therapy*
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives*

Substances

Phosphodiesterase Inhibitors
Thalidomide
apremilast